Jade Biosciences Inc.
JBIO | NASDAQ
$14.08
+$0.02 (+0.14%)
Nov 2, 2026, 10:17 AM ET · Market open
Company Profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Tom Frohlich | President, CEO & Director |
| Elizabeth Balta | Chief Legal Officer & Corporate Secretary |
| Amy Sullivan | Senior Vice President of Development Operations |
| Andrew James King | President of Research & Development |
| Bradford D. Dahms | CFO & Treasurer |
| Edward R. Conner | Chief Medical Officer |
| Jonathan Quick | Senior Vice President of Finance |
| Lori Stewart | Senior Vice President of People |
| Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy |
| Valerie Fauvelle | Senior Vice President of Regulatory & Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 03, 2026 | 424B5 | Filing |
| Jun 01, 2026 | 8-K | Current Report |
| May 15, 2026 | EFFECT | Filing |
| May 15, 2026 | EFFECT | Filing |
| May 15, 2026 | 424B3 | Filing |
| May 15, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 07, 2026 | S-8 | Filing |
| May 07, 2026 | S-3 | Filing |
| May 07, 2026 | S-3 | Filing |
| May 07, 2026 | 424B3 | Filing |
Jade Biosciences Inc.
| Country | United States |
| IPO Date | Jun 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Tom Frohlich |
Contact Details
Building 23 Waltham,
Massachusetts 02453 United States
Stock Details
| Ticker Symbol | JBIO |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001798749 |
| CUSIP Number | 008064206 |
| ISIN Number | US0080642061 |
| SIC Code | n/a |
Recent News
- 2 months ago / globenewswire.comJade Biosciences to Participate in Upcoming Conferences
- 3 months ago / seekingalpha.comJade Biosciences: Duration Is The Real Product
Add to Watchlist
Select watchlists to add or remove JBIO